Neuroprotective Biomolecules from Hericium erinaceus: A Biochemical Perspective

Hericium erinaceus (lion’s mane) is among the most widely marketed natural product preparations for cognitive health and has a long-documented history of use in East Asian traditional medicine alongside botanical drugs. Its principal bioactive constituents, the cyathane diterpenoids, meroterpenoids and structural polysaccharides, belong to the same natural product chemistry, pharmacokinetic and quality control framework applied to plant-derived phytomedicines. Therefore, H. erinaceus faces the same translational questions of batch consistency, bioavailability and mechanistic definition. Scientific evidence remains complicated by the variations in fruiting body and mycelium biochemistry, extraction procedures and pharmacokinetic data. The current work addresses this gap by compiling natural product chemistry, structure–activity relationships, mechanisms of action, preclinical and human studies, along with analytical quality control of H. erinaceus metabolites. It proposes a matrix-specific quality control approach supported by authentication, biochemical makeup and markers for the starting material (fruiting body/mycelium), in addition to critically evaluating the relevant current studies for strengths and weaknesses. Using bioanalytics, mass spectrometry and metabolomics, we also highlight methodologies for compound quantification and novel biomolecule discovery. By linking chemical standardisation to the clinical evidence base, this review provides a quality assessment framework of the kind required for herbal and other natural product remedies. It also identifies the pharmacokinetic and trial design gaps that currently limit integration of these preparations into evidence-based practice.